Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC
If you have scarring of the liver (called cirrhosis), you have a higher chance of developing a type of liver cancer called hepatocellular carcinoma (HCC). Unfortunately, this cancer is often found late, when there are fewer treatment options. This study is testing a new screening method called Elecsys® GAAD. Researchers want to see if using this new test can help doctors find HCC earlier in people with liver cirrhosis, potentially improving their chances of successful treatment. They also want to check if it helps avoid unnecessary extra tests and if people are more likely to stick with their screening appointments using this new approach. The study will compare Elecsys® GAAD with the usual tests currently used.
At a glance
What is this study about?
If you have a condition called liver cirrhosis, which means your liver has a lot of scarring, you have a higher risk of developing a serious type of liver cancer called hepatocellular carcinoma (HCC). Sadly, this cancer is often found at a later stage when it's harder to treat, and this can significantly affect how long someone lives. Currently, the ways we look for this cancer (called surveillance) don't always catch it early enough.
This study is looking at a new blood test called Elecsys® GAAD. The main goal is to see if using this test as part of regular check-ups can help find liver cancer much sooner in people with liver cirrhosis. Finding cancer early often means there are more and better treatment options available.
Researchers are also interested in whether this new test can reduce the number of 'false alarms' – when a test suggests you might have cancer but you don't. This can lead to extra, often uncomfortable, tests that turn out to be unnecessary. Finally, the study wants to understand if this new way of checking for cancer makes it easier for people to attend all their recommended screening appointments. By comparing Elecsys® GAAD to the standard tests, the researchers hope to improve how liver cancer is detected and managed.
Key takeaways
- A new test (Elecsys® GAAD) is being studied to find liver cancer earlier.
- The study is for people with liver scarring (cirrhosis) who are monitored for cancer.
- It aims to improve early detection and reduce unnecessary follow-up tests.
- This could lead to more treatment choices for patients if cancer is found.
- The study compares the new test to standard screening methods.
Who may be eligible?
To be part of this study, you must have been diagnosed with liver cirrhosis and either already be having regular checks for liver cancer or be about to start them. All participants need to be at least 18 years old.
There are certain reasons why you wouldn't be able to join. For example, if you are pregnant or breastfeeding, you won't be able to take part. Also, if you already have liver cancer, or if you don't have liver cirrhosis, this study isn't suitable for you.
It's very important that everyone taking part can understand what the study involves and can make their own decision about joining. The study team will do their best to help people understand, including using interpreters if needed. However, if someone truly can't understand the information well enough to give their consent, they won't be able to join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do you have liver cirrhosis?
- Are you 18 years old or older?
- Are you currently having regular checks for liver cancer, or are you about to start them?
- Are you able to understand information about the study and make your own decision to take part?
- Are you not pregnant or breastfeeding?
- Have you not already been diagnosed with liver cancer?
What does participation involve?
The information provided does not detail specific visits, assessments, medication, or the total duration of participation. Generally, taking part in a study like this might involve giving blood samples for the Elecsys® GAAD test at your regular check-up appointments for liver cancer screening. You would likely continue with your usual standard screening tests alongside the new one. The study would compare the results of the new test with your current screening pathway. There are no details about taking any new medication as part of this study.
Potential risks and benefits
Locations (1)
- Manchester University NHS Foundation TrustVerified postcodeManchester, United Kingdom· Recruiting
Common questions
What is liver cirrhosis?
Liver cirrhosis is a serious condition where your liver is permanently scarred. This scarring can make it harder for your liver to work properly.
What is hepatocellular carcinoma (HCC)?
Hepatocellular carcinoma, or HCC, is the most common type of liver cancer. It often develops in people who have liver cirrhosis.
What is Elecsys® GAAD?
Elecsys® GAAD is a new type of test, likely a blood test, that researchers are hoping could help find liver cancer (HCC) earlier in people with liver cirrhosis.
Why is early detection important for liver cancer?
Finding liver cancer early means there are usually more and better treatment options available, which can improve a patient's chances of recovery and long-term health.
Will this study affect my usual hospital appointments or care?
This study aims to compare a new test with your usual care. It's designed to work alongside your regular check-ups for liver cancer, not to replace them.
How to find out more
Varinder Athwal, PhD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.